IH
Therapeutic Areas
Yuhan Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Leclaza (Lazertinib) | EGFR T790M-mutated Non-Small Cell Lung Cancer (NSCLC) | Approved |
| Jentadueto (Linagliptin/Metformin) | Type 2 Diabetes | Approved |
| Nesina (Alogliptin) | Type 2 Diabetes | Approved |
| YH25448 (Gumarontinib) | EGFR Exon20 Insertion+ NSCLC | Phase 3 |
| YH32367 | HER2-positive Solid Tumors | Phase 1/2 |
| YH29407 | Multiple Myeloma | Phase 1 |
| YH003 | Solid Tumors (e.g., Pancreatic Cancer) | Phase 2 |
| YH001 | Solid Tumors | Phase 2 |
Leadership Team at Yuhan
JH
Jung Hee Lee
Chairman & Chief Executive Officer (CEO)
JH
Jong Hoon Park
Vice Chairman
KC
Ko Chang Park
President & Chief Operating Officer (COO)
SH
Sang Hoon Lee
Chief Financial Officer (CFO) & Head of Management Support Division
IC
In Chul Kim
Head of R&D Division
SW
Seung Wook Lee
Head of Business Division
HK
Hee Kyung Kim
Head of Production Division
JY
Jae Yong Chung
Head of Business Development & Licensing